Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 7/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.34 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3365645 | 0.87 | TSHR (0.41) | TSHRALDH1A1TP53 | |
| SCHEMBL3368005 | 0.83 | TSHR (0.44) | TSHRALDH1A1TP53 | |
| SCHEMBL3368708 | 0.82 | TSHR (0.44) | TSHRALDH1A1CXCR2TP53 | |
| SCHEMBL3367395 | 0.79 | ALDH1A1 (0.43) | TSHRALDH1A1TP53 | |
| SCHEMBL3368371 | 0.79 | TSHR (0.48) | TSHRALDH1A1CXCR2TP53 | |
| SCHEMBL3368356 | 0.79 | TSHR (0.44) | TSHRALDH1A1CXCR2TP53 | |
| SCHEMBL3368020 | 0.79 | TSHR (0.46) | TSHRALDH1A1CXCR2GPR139TP53 | |
| SCHEMBL3367911 | 0.77 | TSHR (0.42) | TSHRALDH1A1CXCR2TP53 | |
| SCHEMBL3367663 | 0.76 | CXCR2 (0.60) | TSHRCETPDYRK1AALDH1A1CXCR2 | |
| SCHEMBL3365515 | 0.76 | TSHR (0.40) | TSHRALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094696-B1 | 5-SULFANYLMETHYL-[1,2,4] TRIAZOL[1, 5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | NOVARTIS AG (CH) | 2010-10-13 | — | — | EP | claimed |
| US-20100069407-A1 | CXCR2 inhibitors | PRESS NEIL JOHN | 2010-03-18 | — | — | US | claimed |
| EP-2094696-A1 | 5-SULFANYLMETHYL-[1,2,4] TRIAZOL[1, 5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | Novartis AG (CH) | 2009-09-02 | — | — | EP | claimed |
| WO-2008061741-A1 | 5-SULFANYLMETHYL-[1,2,4] TRIAZOL[1, 5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | claimed |
| EP-2094696-B1 | 5-SULFANYLMETHYL-[1,2,4] TRIAZOL[1, 5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | NOVARTIS AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| US-20100069407-A1 | CXCR2 inhibitors | PRESS NEIL JOHN | 2010-03-18 | — | — | US | disclosed |
| EP-2094696-A1 | 5-SULFANYLMETHYL-[1,2,4] TRIAZOL[1, 5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008061741-A1 | 5-SULFANYLMETHYL-[1,2,4] TRIAZOL[1, 5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069407-A1 | CXCR2 inhibitors | CXCR2, CXCR1, CXCR3 | TSHR 2129/4885CETP 2259/4885DYRK1A 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.